Viridian Therapeutics Inc (NASDAQ:VRDN) price on Thursday, February 06, fall -3.79% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $18.51.
A look at the stock’s price movement, the close in the last trading session was $19.24, moving within a range at $18.27 and $19.29. The beta value (5-Year monthly) was 1.114. Turning to its 52-week performance, $27.20 and $11.40 were the 52-week high and 52-week low respectively. Overall, VRDN moved -7.77% over the past month.
Viridian Therapeutics Inc’s market cap currently stands at around $1.47 billion, with investors looking forward to this quarter’s earnings report slated for in March.
The average forecast suggests down to a -32.26% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 314.57k, representing a 0.18% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that VRDN is a 50% Sell. On the other hand, the stock is on average a Hold as suggested by medium term indicators while long term indicators are putting the stock in Hold category.
11 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 10 recommend VRDN as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
VRDN’s current price about -0.60% and -4.59% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 45.56, while 7-day volatility ratio is 5.58% and 5.67% in the 30-day chart. Further, Viridian Therapeutics Inc (VRDN) has a beta value of 1.05, and an average true range (ATR) of 1.08. Analysts have given the company’s stock an average 52-week price target of $22, forecast between a low of $19 and high of $28. Looking at the price targets, the low is -2.65% off current price level while to achieve the yearly target high, price needs to move -51.27%. Nonetheless, investors will most likely welcome a -18.85% jump to $22 which is the analysts’ median price.
If we refocus on Viridian Therapeutics Inc (NASDAQ:VRDN), historical trading data shows that trading volumes averaged 1.01 over the past 10 days and 1.42 million over the past 3 months. The company’s latest data on shares outstanding shows there are 79.18 million shares.
The 11.00% of Viridian Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 99.23% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 11.63 million on 2025-01-15, giving us a short ratio of 5.85. The data shows that as of 2025-01-15 short interest in Viridian Therapeutics Inc (VRDN) stood at 1668.0 of shares outstanding, with shares short rising to 9.35 million registered in 2024-12-13. Current price change has pushed the stock -3.44% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the VRDN stock continues to rise going into the next quarter.
